BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HuniLife Biotechnology\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies HuniLife Biotechnology\, Inc.'s d
 rugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07210047-3420@assetmemo.bio
DTSTAMP:20261121T011042Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:HuL001: Phase 1/2 readout est. (NCT07210047)
DESCRIPTION:HuL001\, phase 1/2\, Multiple Myeloma.\nStudy: Study of HuL001 
 in Relapsed/Refractory Multiple Myeloma Patients\nEstimated primary comple
 tion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/hul001#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07210047
URL:https://assetmemo.bio/drug/hul001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
